Antibodies that define unique Meningococcal B epitopes and vaccine compositions
US6048527A · kind A · utility
29Cited by
4References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 27, 1997 |
| Grant date | Apr 11, 2000 |
| Priority date | — |
| Expiry date | Aug 27, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/808
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel bactericidal antibodies against Neisseria meningitidis serogroup B ("MenB") are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.